Xeris Biopharma Holdings' stock price has more than doubled since March, fueled by strong Q3 financial results including a surprise GAAP profit of $0.06 per share, $11.3 million net income, and 44% revenue growth to $107.2 million. The company improved gross margins to 88% and reduced debt by eliminating $34 million in convertible notes, cutting annual interest expenses by $3 million and strengthening its balance sheet. Analysts remain bullish but note that the recent price surge has brought shares near or above several price targets, with potential for further upward revisions following updated guidance. This performance highlights Xeris' growing financial health and investor confidence in its biotech prospects.
Xeris Biopharma's recent financial performance provides context for readers interested in biotech developments. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 12, 2026 23:11 WIB: Among 150 priced US health-sector stocks tradable on Pluang, 39 rose and 111 fell today. Notable movers include ERAS at USD 16.05 with a 1-day change of -4.46%, XRAY at USD 9.35 with a 1-day change of -4.20% and a Pluang order activity of 0% Sell / 100% Buy, and TXG at USD 59.45 with a 1-day change of -4.19% and a typical hold time on Pluang of 92 days.
TRM Labs introduced the Disruption Awards to recognize coalitions of public and private organizations that successfully disrupted major cybercrimes in 2026. Winners include groups that took down a phishing service responsible for most Microsoft-block...
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
atQor has been named a finalist for the 2026 Microsoft Partner of the Year Award in the Agents category, recognized for its innovative and scalable agentic AI solutions deployed across nine industries. The company developed 252 AI agents in FY26, wit...
